Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Gout

In brief

The purpose of the study is to assess the effect of PF-06743649 in lowering serum uric acid in subjects suffering from gout following 14 days of dosing, as well as assessing safety and tolerability.

Key facts

Study ID
NCT02187029
Run by
Pfizer
People needed
30
Starts
2014-07-01
Expected to finish
2014-12-01
Last updated by the study team
2016-11-11

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.